Mutational analysis of the TrkA gene in prostate cancer

Prostate

Volumn 36, Issue 3, 1998, Pages 172-180

  George, Daniel J ^a   Suzuki, Hiroyoshi ^a   Bova, G Steven ^a   Isaacs, John T ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Prostate cancer; Single strand conformation polymorphism; TrkA

Indexed keywords

DNA; NERVE GROWTH FACTOR; TYROSINE KINASE RECEPTOR;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA SEQUENCE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM;

AMINO ACID SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NERVE GROWTH FACTORS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR;

EID: 0031852411     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980801)36:3<172::AID-PROS5>3.0.CO;2-J     Document Type: Article

References (54)

1. Harper GP, Barde Y-A, Burnstock G, Carstairs JR, Denison ME, Suda K, Vernon CA: Guinea pig prostate is a rich source of nerve growth factor. Nature 1979;279:160-162.
2. Cohen S: Purification of a nerve growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Natl Acad Sci USA 1960;46:302-311.
3. Windisch JM, Marksteiner R, Schneider R: Nerve growth factor binding site on TrkA mapped to a single 24-amino acid leucine-rich motif. J Biol Chem 1995;270:28133-28138.
4. Thorpe LW, Perez-Rolo JR: The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. J Neurosci Res 1987;18:134-139.
5. Matsuda H, Coughlin MD, Bienestock J, Denburg JA: Nerve growth factor promotes human hematopoietic colony growth and differentiation. Proc Natl Acad Sci USA 1988;85:6508-6512.
6. Otten U, Baumann SB, Girard J: Stimulation of the pituitary-adrenocortical axis by nerve growth factor. Nature 1979;282: 413-414.
7. Dicou E, Lee J, Brachet P: Synthesis of nerve growth factor mRNA and precursor protein in the thyroid and parathyroid glands of the rat. Proc Natl Acad Sci USA 1986;83:7084-7088.
8. Caramia F, Angeletti PU, Levi-Montaclini, R: Experimental analysis of the mouse submaxillary salivary gland in relationship to its nerve growth factor content. Endocrinology 1962;70: 915-922.
9. Ishii DN, Shooter EM: Regulation of nerve growth factor synthesis in mouse submaxillary glands by testosterone. J Neurochem 1975;25:843-851.
10. Persson H, Ayer-Le Lievre C, Soder O, Villar MJ, Madis Metsis M, Olson L, Ritzen M, Hokfelt T: Expression of β-nerve growth factor receptor mRNA in Sertoli cells downregulated by testosterone. Science 1990;247:704-707.
11. Djakiew D: Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl 1992;13:476-487.
12. Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 1991;51:3304-3310.
13. DeSchryver-Kecskemeti K, Balogh K, Neet E: Nerve growth factor and the concept of neural-epithelial interactions. Arch Pathol Lab Med 1987;111:833-835.
14. MacGrogan D, Saint-Andre J-P, Dicou E: Expression of nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J Neurochem 1992;59:1381-1391.
15. Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch JH, Arand G, Thompson EK: Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 1993;53:1416-1420.
16. Geldof AA, DeKleijn MA, Rao BR, Newling DW: Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J Cancer Res Clin Oncol 1997;123:107-112.
17. Martin-Zanca D, Hughes SH, Barbacid M: A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986;319:743-748.
18. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao M, Parada LF: The trk proto-oncogene product: A signal transducing receptor for nerve growth factor. Science 1991;252:554-558.
19. Klein R, Jing S, Nanduri V, O'Rourke E, Barbacid M: The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991;65:189-197.
20. Graham CW, Lynch JH, Djakiew D: Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 1992;147:1444-1447.
21. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D: Expression of a trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995;136:262-268.
22. Dionne CA, Jani J, Camoratto AM, Emerson E, Neff NT, Vaught J, Murakata C, Djakiew D, Lamb J, Dalrymple S, George D, Isaacs JT: Cell-cycle independent death of prostate adenocarcinoma is induced by the Trk tyrosine kinase inhibitor, CEP-751. Clin Cancer Res 1998 (in press).
23. Kozma SC, Redmond SMS, Xiao-Chang F, Saurer SM, Groner B, Hynes NE: Activation of the receptor kinase domain of the TRK oncogene by recombination with two different cellular sequences. EMBO J 1988;7:147-154.
24. Bongarzone I, Pierotti MA, Monzini N, Mondellini P, Manenti G, Donghi R, Pilotti S, Grieco M, Santoro M, Fusco A, Vecchio G, Della Porta G: High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989;4:1457-1461.
25. Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Van de Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804.
26. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM, Buys CHCM: A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367: 375-376.
27. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
28. Piao X, Berstein A: A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996;87:3117-3123.
29. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheum UR, Feltis JT, Casadevall C, Zamarron A, Bernves M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Zbar B: Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nature Genetics 1997; 16:68-73.
30. Coulier F, Kumar R, Ernst M, Klein R, Martin-Zanca D, Barbacid M: Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol Cell Biol 1990;10:4202-4210.
31. Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-3873.
32. Mellinger GT, Gleason D, Bailar J III: The histology and prognosis of prostatic cancer. J Urol 1967;97:331-337.
33. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990;87:8751-8755.
34. Greco A, Villa R, Pierotti MA: Genomic organization of the human NTRK1 gene. Oncogene 1996;13:2463-2466.
35. Aloe L, Levi-Montalcini R: Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res 1977; 133:358-366.
36. Holden PH, Asopa V, Robertson AGS, Clarke AR, Tyler S, Bennett GS, Brain SD, Wilcock GK, Allen SJ, Smith SKF, Dawbarn D: Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. Nat Biotechnol 1997;15: 668-672.
37. Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, Shooter EM: Tissue-specific alternative splicing generates two isoforms of the trkA receptor. J Biol Chem 1993;268:15150-15157.
38. Katz WS, Lesa GM, Yannoukakos D, Clandinini TR, Schlessinger J, Sternberg PW: A point mutation in the extracellular domain activates LET-23, the Caenorhabditis elegans epidermal growth factor homolog. Mol Cell Biol 1996;16:529-537.
39. Winokur ST, Wasmuth JJ: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994;78:335-342.
40. Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubushi H, Tonoki H, Awaya Y, Matsuda I: Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996;13:485-488.
41. Marrin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M: Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 1989;9:24-33.
42. Glavac D, Dean M: Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat 1993;2:404-414.
43. Hethcote HW, Knudson AG Jr: Model for the incidence of embryonal cancers: Application to retinoblastoma. Proc Natl Acad Sci USA 1978,75:2453-2457.
44. Barde Y-A: Trophic factors and neuronal survival. Neuron 1989; 2:1525-1534.
45. Pflug BR, Onoda M, Lynch JH, Djakiew D: Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 1992;52: 5403-5406.
46. Perez M, Regan T, Pflug B, Lynch J, Djakiew D: Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997;30:274-279.
47. Rabizadeh S, Oh J, Zhong L, Yang J, Bitler C, Butcher LL, Bredesen DE: Induction of apoptosis by the low-affinity NGF receptor. Science 1993;261:345-348.
48. Barrett GL, Bartlett PF: The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. Proc Natl Acad Sci USA 1994;91:6501-6505.
49. Clary DO, Reichardt LF: An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc Natl Acad Sci USA 1994;91: 11133-11137.
50. Baxter GT, Radeke MJ, Kuo RC, Makrides V, Hinkle B, Hoang R, Medina-Selby A, Coit D, Valenzuela P, Feinstein SC: Signal transduction mediated by the truncated trkB receptor isoforms trkB.T1 and trkB.T2. J Neurosci 1997;17:2683-2690.
51. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
52. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK: P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997;94:9052-9057.
53. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycho B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275: 1943-1947.
54. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-362.